about
sameAs
Cognitive enhancers for the treatment of ADHDDrug Development in Alzheimer's Disease: The Contribution of PET and SPECTFrom single target to multitarget/network therapeutics in Alzheimer's therapyMonoamine oxidase inactivation: from pathophysiology to therapeuticsClinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014Interventions to delay functional decline in people with dementia: a systematic review of systematic reviews.Dementia syndromes: evaluation and treatmentPharmacological Treatment of Alzheimer's Disease: Is it Progressing Adequately?Positron emission tomography measurement of brain MAO-B inhibition in patients with Alzheimer's disease and elderly controls after oral administration of sembragiline.Catecholamine-Based Treatment in AD Patients: Expectations and Delusions.Meta-analysis of standardised mean differences from randomised trials with treatment-related clustering associated with care providers.Sembragiline in Moderate Alzheimer's Disease: Results of a Randomized, Double-Blind, Placebo-Controlled Phase II Trial (MAyflOwer RoAD).Amine oxidases and their inhibitors: what can they tell us about neuroprotection and the development of drugs for neuropsychiatric disorders?The effects of rivastigmine plus selegiline on brain acetylcholinesterase, (Na, K)-, Mg-ATPase activities, antioxidant status, and learning performance of aged rats.(-)-Deprenyl alleviates the degenerative changes induced in the neonatal rat spinal cord by CSF from amyotrophic lateral sclerosis patients.Treatment of Alzheimer's disease in Brazil: I. Cognitive disorders.
P2860
Q22251235-2BEF6BAB-83EA-4F91-A265-D8C9ACDD68B0Q26749755-9D028C54-78A6-427E-8278-E5CDA3DE5D9DQ28658200-0BC5414F-AD12-41EB-9D63-4025BE45ED11Q30486227-44D1C6FA-F2DE-4CA3-9139-CE75379AB3CFQ34408888-506445DB-E2D7-464E-9AE7-339159A5FA01Q34523922-D7C657DB-BF4D-4710-B824-3D6D9C4E8CBBQ36787352-6B7E7D6F-BDA7-434E-B0D8-75E18A0075AEQ37198579-71D61F50-DD98-439B-9860-40F33225F2FEQ37614697-C601F62B-BF40-4DCD-9966-485C3C8925A0Q38497202-05979AC0-1EA9-4504-8FE1-1AFCD4396268Q39137368-8CC702B3-0669-4762-A02E-4C1A6405F3D3Q41103337-E75B204E-C930-4E17-90CF-5960B3F24B62Q42399167-D5D095BF-D570-419A-961A-ABC4C4F42FF7Q42531912-54E52878-904F-4F9E-8690-67EE72EB42CEQ45129350-6B541EC1-495F-472E-A79E-7832414C9B02Q47148252-B14EF3AF-6DCF-4FBA-BD07-32D2BC1CF992
P2860
description
2000 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Selegiline for Alzheimer's disease
@ast
Selegiline for Alzheimer's disease
@en
Selegiline for Alzheimer's disease
@en-gb
Selegiline for Alzheimer's disease
@nl
type
label
Selegiline for Alzheimer's disease
@ast
Selegiline for Alzheimer's disease
@en
Selegiline for Alzheimer's disease
@en-gb
Selegiline for Alzheimer's disease
@nl
altLabel
Selegiline for Alzheimer's disease.
@en
prefLabel
Selegiline for Alzheimer's disease
@ast
Selegiline for Alzheimer's disease
@en
Selegiline for Alzheimer's disease
@en-gb
Selegiline for Alzheimer's disease
@nl
P2093
P2860
P3181
P1476
Selegiline for Alzheimer's disease
@en
Selegiline for Alzheimer's disease.
@en
P2093
P2860
P304
P3181
P356
10.1002/14651858.CD000442
P577
2000-01-01T00:00:00Z
2003-01-20T00:00:00Z